140 reports of this reaction
1.3% of all BUROSUMAB reports
#19 most reported adverse reaction
PRODUCT DOSE OMISSION is the #19 most commonly reported adverse reaction for BUROSUMAB, manufactured by Kyowa Kirin, Inc.. There are 140 FDA adverse event reports linking BUROSUMAB to PRODUCT DOSE OMISSION. This represents approximately 1.3% of all 10,519 adverse event reports for this drug.
Patients taking BUROSUMAB who experience product dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION is a less commonly reported adverse event for BUROSUMAB, but still significant enough to appear in the safety profile.
In addition to product dose omission, the following adverse reactions have been reported for BUROSUMAB:
The following drugs have also been linked to product dose omission in FDA adverse event reports:
PRODUCT DOSE OMISSION has been reported as an adverse event in 140 FDA reports for BUROSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION accounts for approximately 1.3% of all adverse event reports for BUROSUMAB, making it a notable side effect.
If you experience product dose omission while taking BUROSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.